{"id":"treprostinil-injectable-product","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Headache"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Flushing"},{"rate":"5-10%","effect":"Pain in extremity"}]},"_chembl":{"chemblId":"CHEMBL1237119","moleculeType":"Small molecule","molecularWeight":"390.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to and activating the prostacyclin receptor, leading to relaxation of smooth muscle cells and vasodilation. This results in decreased blood pressure and reduced platelet aggregation.","oneSentence":"Treprostinil is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:01.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of pulmonary arterial hypertension"},{"name":"Treatment of chronic thromboembolic pulmonary hypertension"}]},"trialDetails":[{"nctId":"NCT01321073","phase":"NA","title":"DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medtronic Cardiac Rhythm and Heart Failure","startDate":"2011-06","conditions":"Pulmonary Arterial Hypertension","enrollment":64},{"nctId":"NCT04062565","phase":"PHASE3","title":"Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2019-03-25","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT02865733","phase":"PHASE3","title":"Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-08-01","conditions":"Pulmonary Hypertension","enrollment":36},{"nctId":"NCT01268553","phase":"PHASE4","title":"Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2010-08","conditions":"Pulmonary Arterial Hypertension","enrollment":6},{"nctId":"NCT03016468","phase":"PHASE2","title":"Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-05","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT00060996","phase":"PHASE3","title":"Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2003-02","conditions":"Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers","enrollment":30},{"nctId":"NCT00067041","phase":"PHASE2, PHASE3","title":"Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft","status":"TERMINATED","sponsor":"United Therapeutics","startDate":"2003-03","conditions":"Peripheral Vascular Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Remodulin"],"phase":"phase_3","status":"active","brandName":"Treprostinil Injectable Product","genericName":"Treprostinil Injectable Product","companyName":"University of Arizona","companyId":"university-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treprostinil is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation. Used for Treatment of pulmonary arterial hypertension, Treatment of chronic thromboembolic pulmonary hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}